The Evolving Landscape of Molecular Alterations in NSCLC: Optimizing Testing and Treatment to Improve Outcomes

Expert oncologists share updates on the testing and treatment of molecular alterations in advanced non-small cell lung cancer.

EP. 1: Overview of Actionable Mutations and Molecular Profiling in NSCLC

April 15th 2022

Expert perspective on the current landscape of actionable mutations and molecular profiling in non–small cell lung cancer management.

EP. 2: Optimizing the Use of Molecular Profiling in Non–Small Cell Lung Cancer

April 15th 2022

Meghan Mooradian, MD, highlights best practices for identifying molecular alterations in NSCLC and addresses barriers to testing.

EP. 3: Is There a Role for IO Therapy in NSCLC With Classical EGFR Mutations or ALK Rearrangements?

April 22nd 2022

Insight on the outcomes seen with immunotherapy in non–small cell lung cancer with classical EGFR mutations or ALK rearrangements in the context of clinical study data.

EP. 4: Poor Outcomes With IO Therapy in NSCLC With Concomitant KRAS/STK11 or KRAS/KEAP1 Mutations

April 22nd 2022

Expert perspective on the poor outcomes observed with immunotherapy in NSCLC with STK11 or KEAP1 mutations, alone or in combination with KRAS alterations.

EP. 5: IO Therapy in NSCLC With Concomitant KRAS/TP53 Mutations

April 29th 2022

Closing out her discussion on the management of actionable mutations in NSCLC, Meghan Mooradian, MD, highlights the detection and implications of KRAS/TP53 mutations.

EP. 6: Molecular Testing in Advanced NSCLC: Recommended Targets and Methods

May 11th 2022

Expert Ticiana Leal, MD, shares her perspective on routine molecular testing practices in advanced non–small cell lung cancer.

EP. 7: Optimizing Use of Molecular Testing in Advanced NSCLC

May 11th 2022

Considerations for optimizing the use of molecular testing in advanced non–small cell lung cancer, addressing insufficient tissue collection and liquid biopsy approaches.

EP. 8: Overcoming Barriers to Molecular Testing in NSCLC

May 18th 2022

After highlighting major barriers to molecular testing in advanced non–small cell lung cancer, Ticiana Leal, MD, provides advice on how to circumvent issues in this setting.

EP. 9: Immunotherapy in NSCLC With Classical EGFR Mutations or ALK Rearrangements

May 18th 2022

A brief review of the lack of efficacy seen with immunotherapy approaches in patients with EGFR-mutated or ALK-rearranged non–small cell lung cancer.

EP. 10: Immunotherapy in NSCLC With Concomitant KRAS/STK11 or KRAS/KEAP1 Mutations

May 25th 2022

Moving on to the KRAS/STK11 and KRAS/KEAP1 setting of non–small cell lung cancer, Ticiana Leal, MD, discusses the lack of benefit seen with immunotherapy approaches.